N6-Methyladenosine Modification of PERP by RBM15 Enhances the Tumorigenesis of Lung Adenocarcinoma Via P53 Signaling Pathway

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2024 Nov 18

PMID 39556280

Authors

Ruiying Li

Xiaochuang Xia

Wenping Chen

Hongmin Wang

Lunda Feng

Zhouyi Wang

Affiliations

Soon will be listed here.

Abstract

The promotive effect of P53 apoptosis effector related to PMP-22 (PERP) on lung adenocarcinoma (LUAD) has been confirmed. However, the N6-methyladenosine (m6A) modification of PERP to regulate LUAD progression have not been revealed. Bioinformatic analysis predicted the mechanism of PERP interacting with RBM15 and p53 pathway using GEPIA and The Cancer Genome Atlas (TCGA) databases. The qRT-PCR, cell function experiments, and western blotting were applied to further confirm the function and mechanism of PERP and RBM15 in LUAD cells. Methylated RNA immunoprecipitation (MeRIP) and mRNA stability assays were used to reveal the interaction between PERP and RBM15 in LUAD cells. PERP with high expression in LUAD showed the poor survival. Silencing PERP prevented LUAD cells to proliferate, migrate, and invade via activating p53 pathway, whereas overexpressing PERP showed the opposite effect on LUAD cells. Mechanistically, RBM15 overexpression could promote PERP m6A modification to enhance the PERP mRNA stability. In addition, RBM15 overexpression leading to LUAD cell malignancy was reversed by PERP knockdown. This study reveals that the mA modification of PERP regulated by RBM15 enhances the tumorigenesis of LUAD by inhibiting the p53 signaling pathway, which may provide novel insights into the LUAD mechanism.

References

Zappa C, Mousa S . Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016; 5(3):288-300. PMC: 4931124. DOI: 10.21037/tlcr.2016.06.07. View

Jurisic V, Vukovic V, Obradovic J, Gulyaeva L, Kushlinskii N, Djordjevic N . Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis. J Oncol. 2020; 2020:1973241. PMC: 7104312. DOI: 10.1155/2020/1973241. View

Lam D, Liam C, Andarini S, Park S, Tan D, Singh N . Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023; 18(10):1303-1322. DOI: 10.1016/j.jtho.2023.06.014. View

Dusek R, Attardi L . Desmosomes: new perpetrators in tumour suppression. Nat Rev Cancer. 2011; 11(5):317-23. PMC: 3799918. DOI: 10.1038/nrc3051. View

Dusek R, Bascom J, Vogel H, Baron S, Borowsky A, Bissell M . Deficiency of the p53/p63 target Perp alters mammary gland homeostasis and promotes cancer. Breast Cancer Res. 2012; 14(2):R65. PMC: 3446400. DOI: 10.1186/bcr3171. View

Shan B, Wang X, Zheng L, Han Y, Gao J, Lv M . DCAF13 promotes breast cancer cell proliferation by ubiquitin inhibiting PERP expression. Cancer Sci. 2022; 113(5):1587-1600. PMC: 9128170. DOI: 10.1111/cas.15300. View

Wang M, Liu J, Zhao Y, He R, Xu X, Guo X . Upregulation of METTL14 mediates the elevation of PERP mRNA N adenosine methylation promoting the growth and metastasis of pancreatic cancer. Mol Cancer. 2020; 19(1):130. PMC: 7446161. DOI: 10.1186/s12943-020-01249-8. View

Liu Z, Han S, Luo Y, Zhao Z, Ni L, Chai L . PERP May Affect the Prognosis of Lung Adenocarcinoma by Inhibiting Apoptosis. Cancer Manag Res. 2024; 16:199-214. PMC: 10961073. DOI: 10.2147/CMAR.S443490. View

Lee Y, Choe J, Park O, Kim Y . Molecular Mechanisms Driving mRNA Degradation by mA Modification. Trends Genet. 2020; 36(3):177-188. DOI: 10.1016/j.tig.2019.12.007. View

10.

Gilbert W, Nachtergaele S . mRNA Regulation by RNA Modifications. Annu Rev Biochem. 2023; 92:175-198. PMC: 11192554. DOI: 10.1146/annurev-biochem-052521-035949. View

11.

Flamand M, Tegowski M, Meyer K . The Proteins of mRNA Modification: Writers, Readers, and Erasers. Annu Rev Biochem. 2023; 92:145-173. PMC: 10443600. DOI: 10.1146/annurev-biochem-052521-035330. View

12.

Lei L, Wang Y, Li Z, Fei L, Huang W, Zheng Y . PHLDA3 promotes lung adenocarcinoma cell proliferation and invasion via activation of the Wnt signaling pathway. Lab Invest. 2021; 101(9):1130-1141. DOI: 10.1038/s41374-021-00608-3. View

13.

Li Y, Sun S, Zhang H, Jing Y, Ji X, Wan Q . CALU promotes lung adenocarcinoma progression by enhancing cell proliferation, migration and invasion. Respir Res. 2024; 25(1):267. PMC: 11227236. DOI: 10.1186/s12931-024-02901-3. View

14.

Liu X, Zhou L, Yuan L, Gao Y, Kui X, Liu X . NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis. Front Immunol. 2021; 12:724741. PMC: 8324208. DOI: 10.3389/fimmu.2021.724741. View

15.

Li K, Peng Z, Wang R, Li X, Du N, Liu D . Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7. Mol Cancer. 2023; 22(1):103. PMC: 10314519. DOI: 10.1186/s12943-023-01811-0. View

16.

Roberts O, Paraoan L . PERP-ing into diverse mechanisms of cancer pathogenesis: Regulation and role of the p53/p63 effector PERP. Biochim Biophys Acta Rev Cancer. 2020; 1874(1):188393. DOI: 10.1016/j.bbcan.2020.188393. View

17.

Hernandez Borrero L, El-Deiry W . Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188556. PMC: 8730328. DOI: 10.1016/j.bbcan.2021.188556. View

18.

Jurisic V, Pavlovic S, Colovic N, Djordjevic V, Bunjevacki V, Jankovic G . Single institute study of FLT3 mutation in acute myeloid leukemia with near tetraploidy in Serbia. J Genet. 2009; 88(2):149-52. DOI: 10.1007/s12041-009-0022-1. View

19.

Marei H, Althani A, Afifi N, Hasan A, Caceci T, Pozzoli G . p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021; 21(1):703. PMC: 8709944. DOI: 10.1186/s12935-021-02396-8. View

20.

Lai J, Chang J, Wen C, Hsu S . Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells. Eur J Pharmacol. 2009; 623(1-3):1-9. DOI: 10.1016/j.ejphar.2009.08.031. View